In 2014, a study was published asse

In 2014, a study was published assessing the efficacy of the Armeo Power in a multi-center randomized trial (Klamroth-Marganska et al., 2014). Seventy-seven chronic stroke patients with moderate to severe paresis were randomized to robotic or conventional therapy for a period of eight weeks. The researchers found that all participants showed improved motor function, but that patients in the robotic therapy group had greater improvements in motor function compared with dose-matched conventional upper limb therapy, with a mean difference of 0.78 points on the Fugl-Meyer. While this change was statistically significant, the difference between robotic and dose-matched conventional therapy is insufficient to be clinically meaningful. Moreover, similar to other studies of upper limb robotic therapy for individuals with chronic hemiparesis, the magnitude of the overall motor improvement is of marginal clinical significance (3.25 points on the upper extremity Fugl-Meyer scale), as compared with the minimum clinically important difference for patients with mild to moderate impairment, approximately 5 points (Page, Fulk, & Boyne, 2012).